Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taxifolin is a naturally occurring flavonoid of the flavanonol subclass, also known as dihydroquercetin. It is found in various plants and foods such as grapes, citrus fruits, onions, green tea, olive oil, and herbs like milk thistle[4][7]. Taxifolin exhibits potent antioxidant activity and has demonstrated anti-inflammatory, antimicrobial (including antibacterial and antifungal), anticancer, hepatoprotective, neuroprotective, anti-hyperlipidemic and cardiovascular protective effects in preclinical studies[3][4][5][7][8]. Mechanistically it acts by scavenging free radicals; inhibiting oxidative stress pathways; modulating inflammatory signaling including NF-κB; suppressing COX-2 and iNOS expression; inducing phase II detoxifying enzymes; suppressing cytochrome P450-dependent monooxygenases; inhibiting apoptosis and cancer cell cycle progression[3][4][5]. Taxifolin can inhibit amyloid-β production via the ApoE-ERK1/2 pathway in models of cerebral amyloid angiopathy[3], block protein aggregation relevant to neurodegenerative diseases[6], act as a non-selective opioid receptor antagonist with weak affinity[7], agonize adiponectin receptor 2 (AdipoR2)[7], inhibit degranulation of mast cells via MAPKs/cPLA2/NF-κB pathways[8], regulate glucose metabolism through PI3K/AKT signaling[8] and maintain lipid homeostasis by reducing cholesterol esterification/synthesis[7]. It is not an approved pharmaceutical drug but is considered experimental for multiple indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on taxifolin.